{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:49Z","timestamp":1790846149965,"version":"4.1.0"},"reference-count":189,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by somatically acquired driver mutations in discrete genes (JAK2, CALR, MPL). In recent years, along with the advances in molecular characterization, the role of immune dysregulation has been achieving increasing relevance in the pathogenesis and evolution of MPNs. In particular, a growing number of studies have shown that MPNs are often associated with detrimental cytokine milieu, expansion of the monocyte\/macrophage compartment and myeloid-derived suppressor cells, as well as altered functions of T cells, dendritic cells and NK cells. Moreover, akin to solid tumors and other hematological malignancies, MPNs are able to evade T cell immune surveillance by engaging the PD-1\/PD-L1 axis, whose pharmacological blockade with checkpoint inhibitors can successfully restore effective antitumor responses. A further interesting cue is provided by the recent discovery of the high immunogenic potential of JAK2V617F and CALR exon 9 mutations, that could be harnessed as intriguing targets for innovative adoptive immunotherapies. This review focuses on the recent insights in the immunological dysfunctions contributing to the pathogenesis of MPNs and outlines the potential impact of related immunotherapeutic approaches.<\/jats:p>","DOI":"10.3390\/ijms22041906","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:53:56Z","timestamp":1613292836000},"page":"1906","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5122-5574","authenticated-orcid":false,"given":"Vincenzo","family":"Nasillo","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL\/AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-6230","authenticated-orcid":false,"given":"Giovanni","family":"Riva","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL\/AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Paolini","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-2216","authenticated-orcid":false,"given":"Luca","family":"Roncati","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Lusenti","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL\/AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Maccaferri","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-2520","authenticated-orcid":false,"given":"Andrea","family":"Messerotti","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pioli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-3536","authenticated-orcid":false,"given":"Andrea","family":"Gilioli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bettelli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Giusti","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Barozzi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lagreca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Maffei","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Potenza","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Comoli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Manfredini","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine \u201cS. Ferrari\u201d, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Maiorana","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-2542","authenticated-orcid":false,"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL\/AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Trenti","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL\/AOU Policlinico, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the Classical Myeloproliferative Neoplasms: The Four Corners of an Expansive and Complex Map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-Term Survival and Blast Transformation in Molecularly Annotated Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Moliterno, A.R., Ginzburg, Y.Z., and Hoffman, R. (2020). Clinical Insights into the Origins of Thrombosis in Myeloproliferative Neoplasms. Blood.","DOI":"10.1182\/blood.2020008043"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The Impact of Myeloproliferative Neoplasms (MPNs) on Patient Quality of Life and Productivity: Results from the International MPN Landmark Survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/bloodadvances.2020002271","article-title":"Leukemic Evolution of Polycythemia Vera and Essential Thrombocythemia: Genomic Profiles Predict Time to Transformation","volume":"4","author":"Riou","year":"2020","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of Myeloproliferative Neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT Signaling in Hematological Malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 Mutations in Myeloproliferative and Other Myeloid Disorders: A Study of 1182 Patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2019.1617129","article-title":"The Role of the Thrombopoietin Receptor MPL in Myeloproliferative Neoplasms: Recent Findings and Potential Therapeutic Applications","volume":"12","author":"Vainchenker","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant Calreticulin Requires Both Its Mutant C-Terminus and the Thrombopoietin Receptor for Oncogenic Transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2018-99-118348","article-title":"Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy","volume":"132","author":"Pecquet","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/HS9.0000000000000333","article-title":"Mutant Calreticulin in the Myeloproliferative Neoplasms","volume":"4","author":"Prins","year":"2020","journal-title":"HemaSphere"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: Document Summary and in-Depth Discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal Evolution and Clinical Correlates of Somatic Mutations in Myeloproliferative Neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Grabek, J., Straube, J., Bywater, M., and Lane, S.W. (2020). MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and Their Effect on Treatment. Cells, 9.","DOI":"10.3390\/cells9081901"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/jcmm.13095","article-title":"Epigenetics in Myeloproliferative Neoplasms","volume":"21","author":"McPherson","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/17474086.2020.1819232","article-title":"Co-Existence of Mutations in Myeloproliferative Neoplasms and Their Clinical Significance: A Prognostic Approach","volume":"13","author":"Pezeshki","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rumi, E., Trotti, C., Vanni, D., Casetti, I.C., Pietra, D., and Sant\u2019Antonio, E. (2020). The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238885"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","article-title":"Sequentially Inducible Mouse Models Reveal That Npm1 Mutation Causes Malignant Transformation of Dnmt3a-Mutant Clonal Hematopoiesis","volume":"33","author":"Loberg","year":"2019","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3109\/10428194.2015.1026900","article-title":"NPM1 Mutations May Reveal Acute Myeloid Leukemia in Cases Otherwise Morphologically Diagnosed as Myelodysplastic Syndromes or Myelodysplastic\/Myeloproliferative Neoplasms","volume":"56","author":"Forghieri","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and Genetic Characterization of Nonacute NPM1-Mutated Myeloid Neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"26. Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., and Riva, G. (2020). NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238975"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Perner, E. (2019). Heidel Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells, 8.","DOI":"10.3390\/cells8080854"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The Regulation of JAKs in Cytokine Signaling and Its Breakdown in Disease","volume":"118","author":"Virtanen","year":"2019","journal-title":"Cytokine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An Immune Dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative Neoplasms and Inflammation: Whether to Target the Malignant Clone or the Inflammatory Process or Both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression and Symptoms","volume":"14","author":"Blackmon","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of Inflammation in the Biology of Myeloproliferative Neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on Chronic Inflammation in Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis: Is Chronic Inflammation a Trigger and Driver of Clonal Evolution and Development of Accelerated Atherosclerosis and Second Cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and Myeloproliferative Neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second Malignancies in Patients with Myeloproliferative Neoplasms: A Population-Based Cohort Study of 9379 Patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Brabrand, M., and Frederiksen, H. (2020). Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers, 12.","DOI":"10.3390\/cancers12103061"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12974-020-01877-3","article-title":"Myeloproliferative Blood Cancers as a Human Neuroinflammation Model for Development of Alzheimer\u2019s Disease: Evidences and Perspectives","volume":"17","author":"Hasselbalch","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bak, M., Jess, T., Flachs, E.M., Zwisler, A.-D., Juel, K., and Frederiksen, H. (2020). Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12092700"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic Inflammation as a Promotor of Mutagenesis in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. A Human Inflammation Model for Cancer Development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Andersen, M., Sajid, Z., Pedersen, R.K., Gudmand-Hoeyer, J., Ellervik, C., Skov, V., Kj\u00e6r, L., Pallisgaard, N., Kruse, T.A., and Thomassen, M. (2017). Mathematical Modelling as a Proof of Concept for MPNs as a Human Inflammation Model for Cancer Development. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183620"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"648090","DOI":"10.1155\/2015\/648090","article-title":"The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Li Volti, G., Giallongo, C., Spampinato, M., Barbagallo, I., Di Rosa, M., Romano, A., Avola, R., Tibullo, D., and Palumbo, G.A. (2020). The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082334"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A Role for Reactive Oxygen Species in JAK2V617F Myeloproliferative Neoplasm Progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2017.00265","article-title":"Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells","volume":"7","author":"Hemmati","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Allegra, A., Pioggia, G., Tonacci, A., Casciaro, M., Musolino, C., and Gangemi, S. (2020). Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR-ABL-Negative Myeloproliferative Neoplasm. Antioxidants, 9.","DOI":"10.3390\/antiox9111037"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal Production of Interleukin (IL)-11 and IL-8 in Polycythaemia Vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum Interleukin (IL)-1, IL-2, SIL-2Ra, IL-6 and Thrombopoietin Levels in Patients with Chronic Myeloproliferative Diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hon.865","article-title":"Evaluation of Circulating Endothelial Cells, VEGF and VEGFR2 Serum Levels in Patients with Chronic Myeloproliferative Diseases","volume":"26","author":"Alonci","year":"2008","journal-title":"Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/030089160909500326","article-title":"Evaluation of Interleukin-17 Serum Levels in Patients with Chronic Myeloproliferative Diseases","volume":"95","author":"Allegra","year":"2009","journal-title":"Tumori"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine Profiles in Polycythemia Vera and Essential Thrombocythemia Patients: Clinical Implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-Inflammatory Cytokines Hepatocyte Growth Factor and Interleukin-11 Are over-Expressed in Polycythemia Vera and Contribute to the Growth of Clonal Erythroblasts Independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101987","DOI":"10.1155\/2015\/101987","article-title":"The Hen or the Egg: Inflammatory Aspects of Murine MPN Models","volume":"2015","author":"Jutzi","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., and Carubbi, C. (2020). Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 9.","DOI":"10.3390\/cells9092136"},{"key":"ref_55","first-page":"5","article-title":"Bone Marrow Fibrosis in Primary Myelofibrosis: Pathogenic Mechanisms and the Role of TGF-\u03b2","volume":"3","author":"Agarwal","year":"2016","journal-title":"Stem Cell Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2012.071183","article-title":"Transcription Factor Nuclear Factor Erythroid-2 Mediates Expression of the Cytokine Interleukin 8, a Known Predictor of Inferior Outcome in Patients with Myeloproliferative Neoplasms","volume":"98","author":"Wehrle","year":"2013","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma Cytokines in Polycythemia Vera: Phenotypic Correlates, Prognostic Relevance, and Comparison with Myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.yexcr.2008.11.020","article-title":"Hypoxia Regulates Inflammatory Gene Expression in Endothelial Cells","volume":"315","author":"Flamant","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis Is an Adverse Prognostic Factor for Survival in Younger Patients with Primary Myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates","volume":"92","author":"Barraco","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine Production in Myelofibrosis Exhibits Differential Responsiveness to JAK-STAT, MAP Kinase, and NF\u03baB Signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective Negative Regulation of Toll-like Receptor Signaling Leads to Excessive TNF-\u03b1 in Myeloproliferative Neoplasm","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2018058","DOI":"10.4084\/mjhid.2018.058","article-title":"The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes Their Osteoclasts More Susceptible to JAK2 Inhibition","volume":"10","author":"Spanoudakis","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of Neoplastic Monocyte-Derived Fibrocytes in Primary Myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","article-title":"Longitudinal Cytokine Profiling Identifies GRO-\u03b1 and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia","volume":"4","author":"Grinfeld","year":"2020","journal-title":"HemaSphere"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2020.01.011","article-title":"Clonal Hematopoiesis and Inflammation: Partners in Leukemogenesis and Comorbidity","volume":"83","author":"Cook","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 Is Required to Resolve Inflammation by Recruiting Hdac2 to Specifically Repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exphem.2017.08.001","article-title":"Tet2 Restrains Inflammatory Gene Expression in Macrophages","volume":"55","author":"Cull","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The Bone Marrow Niche for Haematopoietic Stem Cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2020.01540","article-title":"Regulation of the Bone Marrow Niche by Inflammation","volume":"11","author":"Mitroulis","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid Malignancies and the Microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct Roles for Long-Term Hematopoietic Stem Cells and Erythroid Precursor Cells in a Murine Model of Jak2V617F-Mediated Polycythemia Vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative Neoplasms Can Be Initiated from a Single Hematopoietic Stem Cell Expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","article-title":"Distinct Effects of Concomitant Jak2V617F Expression and Tet2 Loss in Mice Promote Disease Progression in Myeloproliferative Neoplasms","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative Neoplasm Stem Cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000046614","article-title":"Angiogenesis in Chronic Myeloproliferative Diseases","volume":"106","author":"Palumbo","year":"2001","journal-title":"Acta Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.exphem.2015.09.002","article-title":"Dysregulation of VEGF-Induced Proangiogenic Ca2+ Oscillations in Primary Myelofibrosis-Derived Endothelial Colony-Forming Cells","volume":"43","author":"Dragoni","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"869242","DOI":"10.1155\/2015\/869242","article-title":"Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms","volume":"2015","author":"Hoermann","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone Marrow Fibrosis in Myelofibrosis: Pathogenesis, Prognosis and Targeted Strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood-2004-04-1320","article-title":"A Pathobiologic Pathway Linking Thrombopoietin, GATA-1, and TGF-Beta1 in the Development of Myelofibrosis","volume":"105","author":"Vannucchi","year":"2005","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1111\/jcmm.15526","article-title":"Transforming Growth Factor \u03b2-Mediated Micromechanics Modulates Disease Progression in Primary Myelofibrosis","volume":"24","author":"Teodorescu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 Expression in Hematopoietic Cells Links Inflammation and Progression of Bone Marrow Fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ramos, T.L., S\u00e1nchez-Abarca, L.I., Ros\u00f3n-Burgo, B., Redondo, A., Rico, A., Preciado, S., Ortega, R., Rodr\u00edguez, C., Munti\u00f3n, S., and Hern\u00e1ndez-Hern\u00e1ndez, \u00c1. (2017). Mesenchymal Stromal Cells (MSC) from JAK2+ Myeloproliferative Neoplasms Differ from Normal MSC and Contribute to the Maintenance of Neoplastic Hematopoiesis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182470"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-Receptor-Expressing Bone Marrow Stromal Cells Are Myofibroblasts in Primary Myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Pilling, D., Fan, T., Huang, D., Kaul, B., and Gomer, R.H. (2009). Identification of Markers That Distinguish Monocyte-Derived Fibrocytes from Monocytes, Macrophages, and Fibroblasts. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007475"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Manshouri, T., Verstovsek, S., Harris, D.M., Veletic, I., Zhang, X., Post, S.M., Bueso-Ramos, C.E., and Estrov, Z. (2019). Primary Myelofibrosis Marrow-Derived CD14+\/CD34- Monocytes Induce Myelofibrosis-like Phenotype in Immunodeficient Mice and Give Rise to Megakaryocytes. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222912"},{"key":"ref_92","unstructured":"Eyden, B. (2007). The Myofibroblast: A Study of Normal, Reactive and Neoplastic Tissues, with an Emphasis on Ultrastructure. J. Submicrosc. Cytol. Pathol., 7\u2013296."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1582-4934.2007.00213.x","article-title":"The Myofibroblast: Phenotypic Characterization as a Prerequisite to Understanding Its Functions in Translational Medicine","volume":"12","author":"Eyden","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"415024","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis","volume":"2015","author":"Desterke","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of Haematopoietic Stem Cell Niche Is Essential for Myeloproliferative Neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2141.2002.03874.x","article-title":"Plasma Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinase in Patients with Agnogenic Myeloid Metaplasia or Idiopathic Primary Myelofibrosis","volume":"119","author":"Wang","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_97","first-page":"140","article-title":"[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells]","volume":"38","author":"Liu","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl Oxidase: An Oxidative Enzyme and Effector of Cell Function","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"27630","DOI":"10.1074\/jbc.M111.243113","article-title":"Control of Megakaryocyte Expansion and Bone Marrow Fibrosis by Lysyl Oxidase","volume":"286","author":"Eliades","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of Lysyl Oxidase and Adhesion to Collagen of Human Megakaryocytes and Platelets in Primary Myelofibrosis","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The Expression of Lysyl-Oxidase Gene Family Members in Myeloproliferative Neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular Profiling of Peripheral Blood Cells from Patients with Polycythemia Vera and Related Neoplasms: Identification of Deregulated Genes of Significance for Inflammation and Immune Surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum from Essential Thrombocythemia over Polycythemia Vera to Myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","article-title":"Whole Blood Transcriptional Profiling Reveals Significant Down-Regulation of Human Leukocyte Antigen Class I and II Genes in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis","volume":"54","author":"Skov","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of Circulating CD56 bright Natural Killer Cells in Patients with JAK2-Positive Chronic Myeloproliferative Neoplasms during Treatment with Interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","article-title":"Mutations in JAK2 and Calreticulin Genes Are Associated with Specific Alterations of the Immune System in Myelofibrosis","volume":"6","author":"Romano","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2018-05-850321","article-title":"Murine Myeloproliferative Disorder as a Consequence of Impaired Collaboration between Dendritic Cells and CD4 T Cells","volume":"133","author":"Barber","year":"2019","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in Circulating CD4+CD25+Foxp3+ T Cells in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms during Treatment with IFN-\u03b1","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","article-title":"JAK Inhibition Induces Silencing of T Helper Cytokine Secretion and a Profound Reduction in T Regulatory Cells","volume":"171","author":"Keohane","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1097\/HS9.0000000000000168","article-title":"Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets","volume":"3","author":"Bizymi","year":"2019","journal-title":"HemaSphere"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-Derived Suppressor Cells in Patients with Myeloproliferative Neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Rachidi, S., Metelli, A., Riesenberg, B., Wu, B.X., Nelson, M.H., Wallace, C., Paulos, C.M., Rubinstein, M.P., Garrett-Mayer, E., and Hennig, M. (2017). Platelets Subvert T Cell Immunity against Cancer via GARP-TGF\u03b2 Axis. Sci. Immunol., 2.","DOI":"10.1126\/sciimmunol.aai7911"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2 V617F Causes PD-L1 Expression, Mediating Immune Escape in Myeloproliferative Neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/10428194.2017.1359743","article-title":"Sorted Peripheral Blood Cells Identify CALR Mutations in B- and T-Lymphocytes","volume":"59","author":"Kjaer","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","article-title":"Immunosuppression by Mutated Calreticulin Released from Malignant Cells","volume":"77","author":"Liu","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-Cell Product Performance in Haematological Malignancies before and after Marketing Authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T Cell-Engaging Therapies\u2014BiTEs and Beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in Hematologic Malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and Dynamics of Robust T-Cell Responses to CML under Imatinib Treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2009-06-230391","article-title":"Emergence of BCR-ABL-Specific Cytotoxic T Cells in the Bone Marrow of Patients with Ph+ Acute Lymphoblastic Leukemia during Long-Term Imatinib Mesylate Treatment","volume":"115","author":"Riva","year":"2010","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1038\/bcj.2011.26","article-title":"BCR-ABL-Specific Cytotoxic T Cells in the Bone Marrow of Patients with Ph(+) Acute Lymphoblastic Leukemia during Second-Generation Tyrosine-Kinase Inhibitor Therapy","volume":"1","author":"Riva","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated Regions of Nucleophosmin 1 Elicit Both CD4(+) and CD8(+) T-Cell Responses in Patients with Acute Myeloid Leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"869","DOI":"10.18632\/oncotarget.26617","article-title":"Characterization and Dynamics of Specific T Cells against Nucleophosmin-1 (NPM1)-Mutated Peptides in Patients with NPM1-Mutated Acute Myeloid Leukemia","volume":"10","author":"Forghieri","year":"2019","journal-title":"Oncotarget"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2008-04-149393","article-title":"Differential Pattern of CD4+ and CD8+ T-Cell Immunity to MAGE-A1\/A2\/A3 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma","volume":"112","author":"Goodyear","year":"2008","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2016-07-731091","article-title":"BCR-ABL-Specific T-Cell Therapy in Ph+ ALL Patients on Tyrosine-Kinase Inhibitors","volume":"129","author":"Comoli","year":"2017","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood-2016-12-757336","article-title":"Fall of the Mutants: T Cells Targeting BCR-ABL","volume":"129","author":"Lulla","year":"2017","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F Mutation Is a Target for Specific T Cells in the JAK2V617F-Positive Myeloproliferative Neoplasms","volume":"31","author":"Ahmad","year":"2017","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR Exon 9 Mutations Are Shared Neoantigens in Patients with CALR Mutant Chronic Myeloproliferative Neoplasms","volume":"30","author":"Riley","year":"2016","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The Calreticulin (CALR) Exon 9 Mutations Are Promising Targets for Cancer Immune Therapy","volume":"32","author":"Martinenaite","year":"2018","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms","volume":"9","author":"Roudko","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High Frequencies of Circulating Memory T Cells Specific for Calreticulin Exon 9 Mutations in Healthy Individuals","volume":"9","author":"Ahmad","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","article-title":"Spontaneous T-Cell Responses against the Immune Check Point Programmed-Death-Ligand 1 (PD-L1) in Patients with Chronic Myeloproliferative Neoplasms Correlate with Disease Stage and Clinical Response","volume":"7","author":"Riley","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e1468957","DOI":"10.1080\/2162402X.2018.1468957","article-title":"Spontaneous T-Cell Responses against Arginase-1 in the Chronic Myeloproliferative Neoplasms Relative to Disease Stage and Type of Driver Mutation","volume":"7","author":"Martinenaite","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-Art Review: Allogeneic Stem Cell Transplantation for Myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clml.2017.08.002","article-title":"The Treatment Landscape of Myelofibrosis before and After Ruxolitinib Approval","volume":"17","author":"Kuykendall","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","article-title":"Does Ruxolitinib Prolong the Survival of Patients with Myelofibrosis?","volume":"129","author":"Cervantes","year":"2017","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-Term Treatment with Ruxolitinib for Patients with Myelofibrosis: 5-Year Update from the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients with Myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11899-020-00596-z","article-title":"The Next Generation of JAK Inhibitors: An Update on Fedratinib, Momelotonib, and Pacritinib","volume":"15","author":"Patel","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of Myelofibrosis after Ruxolitinib Failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal Evolution and Outcomes in Myelofibrosis after Ruxolitinib Discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal Contributions of Megakaryocytes to the Biology of Idiopathic Myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e2018068","DOI":"10.4084\/mjhid.2018.068","article-title":"Megakaryocyte Contribution to Bone Marrow Fibrosis: Many Arrows in the Quiver","volume":"10","author":"Malara","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide Compared with Hydroxyurea in WHO-Classified Essential Thrombocythemia: The ANAHYDRET Study, a Randomized Controlled Trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jth.12850","article-title":"Anagrelide Platelet-Lowering Effect Is Due to Inhibition of Both Megakaryocyte Maturation and Proplatelet Formation: Insight into Potential Mechanisms","volume":"13","author":"Espasandin","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Magnaghi-Jaulin, L., Eot-Houllier, G., Gallaud, E., and Giet, R. (2019). Aurora A Protein Kinase: To the Centrosome and Beyond. Biomolecules, 9.","DOI":"10.3390\/biom9010028"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1182\/blood-2003-09-3365","article-title":"Aberrant Quantity and Localization of Aurora-B\/AIM-1 and Survivin during Megakaryocyte Polyploidization and the Consequences of Aurora-B\/AIM-1-Deregulated Expression","volume":"103","author":"Zhang","year":"2004","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-Specific Demethylase 1 Restricts Hematopoietic Progenitor Proliferation and Is Essential for Terminal Differentiation","volume":"26","author":"Schulte","year":"2012","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"HemaSphere"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2019-123244","article-title":"A Phase 2a Study of the LSD1 Inhibitor Img-7289 (Bomedemstat) for the Treatment of Myelofibrosis","volume":"134","author":"Pettit","year":"2019","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"S828 A Randomized, Double Blind Phase 2 Study of 3 Different Doses of PRM-151 in Patients with Myelofibrosis who Were Previously Treated with or Ineligible for Ruxolitinib","volume":"3","author":"Verstovsek","year":"2019","journal-title":"HemaSphere"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/1878-0261.12387","article-title":"Role of TGF-\u03921\/MiR-382-5p\/SOD2 Axis in the Induction of Oxidative Stress in CD34+ Cells from Primary Myelofibrosis","volume":"12","author":"Rossi","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal Cell-Mediated Inhibition of Erythropoiesis Can Be Attenuated by Sotatercept (ACE-011), an Activin Receptor Type II Ligand Trap","volume":"41","author":"Mosoyan","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An Activin Receptor IIA Ligand Trap Promotes Erythropoiesis Resulting in a Rapid Induction of Red Blood Cells and Haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"HemaSphere"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the Treatment of Anemia in Myelodysplastic Syndromes and Primary Myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V128.22.478.478","article-title":"Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia","volume":"128","author":"Bose","year":"2016","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2018-99-116474","article-title":"AVID200, a Potent Trap for TGF-\u03b2 Ligands Inhibits TGF-\u03921 Signaling in Human Myelofibrosis","volume":"132","author":"Varricchio","year":"2018","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-Transforming Growth Factor-\u03b2 Therapy in Patients with Myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","article-title":"Efficacy of ALK5 Inhibition in Myelofibrosis","volume":"2","author":"Yue","year":"2017","journal-title":"JCI Insight"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3324\/haematol.2018.211896","article-title":"Exploitation of the Neural-Hematopoietic Stem Cell Niche Axis to Treat Myeloproliferative Neoplasms","volume":"104","author":"Herlihy","year":"2019","journal-title":"Haematologica"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3324\/haematol.2018.200014","article-title":"The Sympathomimetic Agonist Mirabegron Did Not Lower JAK2-V617F Allele Burden, but Restored Nestin-Positive Cells and Reduced Reticulin Fibrosis in Patients with Myeloproliferative Neoplasms: Results of Phase II Study SAKK 33\/14","volume":"104","author":"Drexler","year":"2019","journal-title":"Haematologica"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1038\/bcj.2017.6","article-title":"The Role of the Extracellular Matrix in Primary Myelofibrosis","volume":"7","author":"Leiva","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The Lysyl Oxidase like 2\/3 Enzymatic Inhibitor, PXS-5153A, Reduces Crosslinks and Ameliorates Fibrosis","volume":"23","author":"Schilter","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel Lysyl Oxidase Inhibitors Attenuate Hallmarks of Primary Myelofibrosis in Mice","volume":"110","author":"Leiva","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bjh.14501","article-title":"A Phase 2 Study of Simtuzumab in Patients with Primary, Post-Polycythaemia Vera or Post-Essential Thrombocythaemia Myelofibrosis","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","article-title":"Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis. A Study of the AGIMM Group on 490 Patients","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V89.5.1471","article-title":"The Structural and Functional Basis of Cytokine Receptor Activation: Lessons from the Common Beta Subunit of the Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-3 (IL-3), and IL-5 Receptors","volume":"89","author":"Bagley","year":"1997","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 Cytokine Receptor Family: From Ligand Recognition to Initiation of Signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"El Achi, H., Dupont, E., Paul, S., and Khoury, J.D. (2020). CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113087"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 Is a Membrane Biomarker and a Therapeutic Target in Hematologic Malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2015.16","article-title":"Aberrant Expression of CD123 (Interleukin-3 Receptor-\u03b1) on Neoplastic Mast Cells","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The Interleukin-3 Receptor Alpha Chain Is a Unique Marker for Human Acute Myelogenous Leukemia Stem Cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated Expression of IL-3R\u03b1 in Acute Myelogenous Leukemia Is Associated with Enhanced Blast Proliferation, Increased Cellularity, and Poor Prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1182\/blood.V124.21.5577.5577","article-title":"Expression of CD123 (IL-3R-Alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms","volume":"124","author":"Lasho","year":"2014","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3324\/haematol.2018.188193","article-title":"The Interleukin-3 Receptor CD123 Targeted SL-401 Mediates Potent Cytotoxic Activity against CD34+CD123+ Cells from Acute Myeloid Leukemia\/Myelodysplastic Syndrome Patients and Healthy Donors","volume":"103","author":"Mani","year":"2018","journal-title":"Haematologica"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","article-title":"Targeting CD123 in AML","volume":"20","author":"Lane","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2019-131217","article-title":"Results from a Phase 1\/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed\/Refractory Myelofibrosis","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"5825401","DOI":"10.1155\/2020\/5825401","article-title":"Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy","volume":"2020","author":"Igarashi","year":"2020","journal-title":"J. Immunol. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1906\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:12Z","timestamp":1760160252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":189,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041906"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041906","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]}}}